The9's Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting

IPO/OfferingPositive

AI Analysis

Summary

The9 Limited's investee Nanyang Biologics has cleared a shareholder vote on the RFAI for a planned Nasdaq listing, with The9 expecting to hold approximately 15-16% of the combined company following the transaction.

Outcome Details

Shareholders voted to clear RFAI (Reverse Merger Agreement Item) for Nasdaq listing

Importance:6/10

Sentiment:

0.70

Nasdaq listingIPOshareholder voteAI-driven drug discoverystrategic investment

Related Companies

$NCTY

Read the original article

Published by PR Newswire Biotech on August 21, 2026 12:30 PM

Read Original